Low Toxicity in Inflammatory Bowel Disease Patients Treated With Abdominal and Pelvic Radiation Therapy

被引:25
|
作者
White, Evan C. [1 ]
Murphy, James D. [1 ]
Chang, Daniel T. [1 ]
Koong, Albert C. [1 ]
机构
[1] Stanford Univ, Sch Med, Dept Radiat Oncol, Stanford Canc Inst, Stanford, CA 94305 USA
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2015年 / 38卷 / 06期
关键词
inflammatory bowel disease; toxicity; intensity-modulated radiation therapy (IMRT); RADIOTHERAPY; CANCER; SURGERY; HISTORY; TRIAL; RISK;
D O I
10.1097/COC.0000000000000010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective:To determine the short-term and long-term toxicity of abdominal and pelvic radiation therapy in a cohort of patients with inflammatory bowel disease (IBD). We hypothesize that with newer techniques, such as intensity-modulated radiation therapy (IMRT) and 3-dimensional conformal radiotherapy (3D-CRT), patients with IBD can safely undergo abdominal and pelvic radiation, with low risk for major acute or late toxicity.Materials and Methods:Nineteen consecutive patients with IBD (14 with ulcerative colitis, 5 with Crohn disease) who were treated with abdominal or pelvic external beam radiation therapy at Stanford University from 1997 to 2011 were identified. Fourteen patients were treated with IMRT and 5 were treated with 3D-CRT. Treated sites included prostate (n=8), gastric/esophageal (n=5), rectal/anal (n=3), and liver (n=3) tumors. Charts were reviewed and toxicity was graded according to the Common Terminology Criteria for Acute Events version 4.0. Median follow-up was 32.5 months. Fisher exact test was used to determine if any clinical and/or treatment factors were associated with toxicity outcomes.Results:Acute grade 3 toxicity occurred in 2 patients (11%). Late grade 3 toxicity occurred in 1 patient (6%). Acute grade 2 toxicity occurred in 28% of patients treated with IMRT versus 100% of patients treated with 3D-CRT (P=0.01). Acute grade 2 gastrointestinal toxicity was lower in patients treated with IMRT versus 3D-CRT (14% vs. 100%, respectively, P=0.002). Late grade 2 toxicity occurred in 21% of patients. Higher total dose (Gy) and biologically effective dose (Gy) were associated with increased rates of late grade 2 toxicity (P=0.02 and 0.03, respectively).Conclusions:These data suggest that select patients with IBD can safely undergo abdominal and pelvic radiation therapy. The use of IMRT was associated with decreased acute toxicity. Acute and late severe toxicity rates were low in this patient population with the use of modern radiation techniques.
引用
收藏
页码:564 / 569
页数:6
相关论文
共 50 条
  • [31] EPIDEMIOLOGICAL PROFILE, GASTROINTESTINAL TOXICITY, AND TREATMENT OF PELVIC CANCERS IN PATIENTS MANAGED WITH RADIOTHERAPY TO THE ABDOMINAL PELVIC AREA
    Cetina-Perez, Lucely
    Serrano-Olvera, Alberto
    Flores-Cisneros, Laura
    Jimenez-Lima, Roberto
    Alvarado-Silva, Cristina
    del Consuelo Diaz-Romero, Maria
    Morales-Vasquez, Flavia
    Eduardo Munoz-Gonzalez, David
    Mota-Garcia, Aida
    Armando Chavez-Fierro, Oscar
    Cristina Jaramillo-Manzur, Silvia
    de la Garza-Salazar, Jaime
    Castro-Eguiluz, Denisse
    Meneses-Garcia, Abelardo
    REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2018, 70 (03): : 112 - 116
  • [32] Postoperative outcomes in vedolizumab-treated pediatric patients undergoing abdominal operations for inflammatory bowel disease
    Lightner, Amy L.
    Tse, Chung Sang
    Potter, D. Dean, Jr.
    Moir, Christopher
    JOURNAL OF PEDIATRIC SURGERY, 2018, 53 (09) : 1706 - 1709
  • [33] Vaccination therapy for inflammatory bowel disease
    Liu, Yafei
    Liao, Fei
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (02)
  • [34] Stereotactic body radiation therapy for the treatment of localized prostate cancer in men with underlying inflammatory bowel disease
    Lischalk, Jonathan W.
    Blacksburg, Seth
    Mendez, Christopher
    Repka, Michael
    Sanchez, Astrid
    Carpenter, Todd
    Witten, Matthew
    Garbus, Jules E.
    Evans, Andrew
    Collins, Sean P.
    Katz, Aaron
    Haas, Jonathan
    RADIATION ONCOLOGY, 2021, 16 (01)
  • [35] Safety of Radiation Therapy in Patients With Prostate Cancer and Inflammatory Bowel Disease: A Systematic Review
    Trotta, Matthew
    Patel, Krishnan R.
    Singh, Sarah
    Verma, Vivek
    Ryckman, Jeffrey
    PRACTICAL RADIATION ONCOLOGY, 2023, 13 (05) : 454 - 465
  • [36] Abdominal Emergencies in Inflammatory Bowel Disease
    Goldstone, Robert N.
    Steinhagen, Randolph M.
    SURGICAL CLINICS OF NORTH AMERICA, 2019, 99 (06) : 1141 - +
  • [37] Ionizing radiation exposure in patients with inflammatory bowel disease: Are we overexposing our patients?
    Estay, Camila
    Simian, Daniela
    Lubascher, Jaime
    Figueroa, Carolina
    O'Brien, Andres
    Quera, Rodrigo
    JOURNAL OF DIGESTIVE DISEASES, 2015, 16 (02) : 83 - 89
  • [38] Which patients with inflammatory bowel disease should receive combination therapy?
    Cross, Raymond K.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2015, 9 (06) : 715 - 717
  • [39] Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease
    Abu-Sbeih, Hamzah
    Faleck, David M.
    Ricciuti, Biagio
    Mendelsohn, Robin B.
    Naqash, Abdul R.
    Cohen, Justine V.
    Sellers, Maclean C.
    Balaji, Aanika
    Ben-Betzalel, Guy
    Hajir, Ibraheim
    Zhang, Jiajia
    Awad, Mark M.
    Leonardi, Giulia C.
    Johnson, Douglas B.
    Pinato, David J.
    Owen, Dwight H.
    Weiss, Sarah A.
    Lamberti, Giuseppe
    Lythgoe, Mark P.
    Manuzzi, Lisa
    Arnold, Christina
    Qiao, Wei
    Naidoo, Jarushka
    Markel, Gal
    Powell, Nick
    Yeung, Sai-Ching J.
    Sharon, Elad
    Dougan, Michael
    Wang, Yinghong
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06) : 576 - +
  • [40] Is abdominal CT useful for the management of patients with severe acute colitis complicating inflammatory bowel disease? A study in 54 consecutive patients
    Mege, D.
    Monsinjon, M.
    Zappa, M.
    Stefanescu, C.
    Treton, X.
    Maggiori, L.
    Bouhnik, Y.
    Panis, Y.
    COLORECTAL DISEASE, 2017, 19 (04) : O97 - O102